undamentalytics Newsletter
Sign in

Kymera Therapeutics, Inc. (KYMR) stock

Add to watchlist

Add holding +

NASDAQ: KYMR Nasdaq Biotechnology Next results ~January 15, 2027

C Fundamentals grade

Kymera Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Kymera Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Kymera Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 11 selling2 purchases and 274 sales by directors and officers, last 12 monthsInsider trades
  • Funds141 adding, 109 cuttingOf 48 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Kymera Therapeutics files

Where Kymera Therapeutics stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $102m, up 133.8% on a year earlier, slower than the 134.8% growth a quarter earlier. That growth ranks 23 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -282.6% from -526.4% a year earlier. Operating margin widened to -396.0% from -759.7%. The diluted share count is up 17.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Our model value for Kymera Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 15, 2027 (estimated)

Kymera Therapeutics, Inc.'s trailing-twelve-month revenue grew 133.8% year on year, with a free-cash-flow margin of -282.6%. Where it stands out: revenue growth of 133.8% ranks 33 of 172 biotechnology companies we cover. Where it lags: gross margin of 0.0% ranks 75 of 75 biotechnology companies we cover.

Current signal Operating margin expanding: TTM operating margin reached -396.0%, up 363.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 133.8% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 363.7 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.4bn.

Things to watch

  • Loss-making. Operating margin is -396.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -282.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 66.7% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 17.6% in a year.
  • High sales multiple. The shares trade at 120 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 62% and a beta of 0.8 against the S&P 500.

Latest results: FY2026 Q3

Filed October 29, 2026
Earnings per share
-$1.32 against an average estimate of -$1.27: missed by 4.2%
Share reaction
+3.4% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Next report
October 29, 2026; average EPS estimate -$1.26

Kymera Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.7%
  • 1 week+11.0%
  • 1 month+18.7%
  • This year+63.9%
  • 1 year+106.2%
  • 5 years+95.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$102M
Operating margin
-396.0%
Net margin
-341.8%
EPS (TTM, diluted)
$-3.62

Growth

Revenue growth
+133.8%
Change in growth rate
−1.1 pts
Share count change
+17.6%

Cash

Free cash flow (TTM)
-$289M
FCF margin
-282.6%
Stock pay % of revenue
66.7%

Earnings

Last results
October 29, 2026
Next results (est.)
January 15, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Insider trade
  3. Results
  4. Leadership
  5. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Kymera Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Kymera Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.31 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.6 ~$9.5–$9.7 Left out: out of range vs price (0.08x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.8 ~$1.8–$6.8 Left out: out of range vs price (0.01x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kymera Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$62.00$63.49$24.96$25.46$40.23$77.81$127.51
Market value$1.1bn$3.0bn$1.3bn$1.5bn$3.0bn$6.6bn$12.3bn
+ Net debt (− = net cash)−$31m−$48m−$68m−$110m−$120m−$357m−$373m
Enterprise value$1.0bn$3.0bn$1.3bn$1.4bn$2.9bn$6.2bn$11.9bn
Multiples
Price / sales 31.6x41.8x28.7x18.9x64.1x167.7x120.3x
Price / earnings ———————
Price / free cash flow 13.6x——————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

14 /100

Weak moat

How hard Kymera Therapeutics's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -19.8% of total assets over 7 years.

  • Durability 10 / 20

    Operating margin has been a median -340.8%; its worst year was -759.7%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -282.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (19 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.85 −4% $99m +154%
Next −$5.10 −33% $49m −51%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +9.6% on 90 days ago. In the last 30 days, 3 analysts raised Kymera Therapeutics, Inc.'s forecast and 11 cut it.

Consensus EPS forecast Kymera Therapeutics, Inc., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.51 Current fiscal year, 60 days ago: −$3.78 Current fiscal year, 30 days ago: −$3.84 Current fiscal year, 7 days ago: −$3.85 Current fiscal year, Now: −$3.85 −$3.85 Next fiscal year, 90 days ago: −$4.36 Next fiscal year, 60 days ago: −$4.94 Next fiscal year, 30 days ago: −$5.10 Next fiscal year, 7 days ago: −$5.10 Next fiscal year, Now: −$5.10 −$5.10

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.51−$4.36
60 days ago −$3.78−$4.94
30 days ago −$3.84−$5.10
7 days ago −$3.85−$5.10
Now −$3.85−$5.10

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$1.27 −$1.32 −4.2%
Jun 2026 −$0.74 −$0.62 +16.0%
Mar 2026 −$0.86 −$0.71 +17.1%
Dec 2025 −$0.77 −$0.98 −27.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

24 analysts, Oct 2026
Buy2292%
Hold28%
Sell00%

Monthly trend

  1. Oct 2026517224
  2. Sep 2026417223
  3. Aug 2026417324
  4. Jul 2026417324

Counts of recommendations published by analysts covering Kymera Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.7%
of tradable shares
Days to cover
10.32
at average volume
Short interest, 1 month
−13%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
2.1%
of shares
Employees
238
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +106.2%

$61.84 on October 31, 2025 to $127.51

ThenNowEffect
Revenue (last 12 months) $45m $105m +134.8%
P/S multiple 109.6x 113.3x +3.4%
Share count 79m 93m −15.0%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
KYMR+2%−61%+2%+58%+93%+64%
Industry peers (median)−36%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
KYMR58%42%33%42%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
KYMR−64%−78%−72%−32%−53%−25%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since August 21, 2020: 88% from December 28, 2020 to October 27, 2023. Getting back needed a 701% gain, reached on December 8, 2025, 773 days after the low.

Price behaviour

52-week range
$58.66 – $127.51
From 52-week high
0.0%
vs 50-day average
+10.8%
vs 200-day average
+31.9%
Volatility (1 year)
62%
Beta vs S&P 500
0.75

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±4.1%
After a week
7 up, 4 down
typical move ±6.7%
After a month
7 up, 4 down
typical move ±13.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 +3.4% −2.1% — —
August 5, 2026 +1.9% −0.4% +9.2% +12.3%
April 30, 2026 −1.0% +1.3% +3.8% −3.7%
February 26, 2026 +0.7% −1.0% −7.9% −13.8%
January 13, 2026 +2.9% −0.7% −3.2% +15.0%
November 4, 2025 +0.3% −0.8% +6.1% +10.9%
August 11, 2025 −1.8% +0.9% +7.4% +7.0%
May 9, 2025 +4.5% +3.2% −1.7% +57.9%
February 27, 2025 −11.3% −0.1% −8.0% −16.2%
January 14, 2025 +17.0% +2.0% +18.6% −1.6%
October 31, 2024 −2.5% −1.5% +4.6% +0.1%
August 7, 2024 +1.4% +1.6% +2.7% +9.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Kymera Therapeutics, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Kymera Therapeutics, Inc.
$20M $40M $60M $80M $100M $120M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $78.6M Revenue (TTM), FY24 Q1: $79.4M Revenue (TTM), FY24 Q2: $88.6M Revenue (TTM), FY24 Q3: $87.6M Revenue (TTM), FY24 Q4: $47.1M Revenue (TTM), FY25 Q1: $58.9M Revenue (TTM), FY25 Q2: $44.7M Revenue (TTM), FY25 Q3: $43.7M Revenue (TTM), FY25 Q4: $39.2M Revenue (TTM), FY26 Q1: $51.5M Revenue (TTM), FY26 Q2: $105M Revenue (TTM), FY26 Q3: $102.2M $102.2M

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $78.6M
FY24 Q1 $79.4M
FY24 Q2 $88.6M
FY24 Q3 $87.6M
FY24 Q4 $47.1M
FY25 Q1 $58.9M
FY25 Q2 $44.7M
FY25 Q3 $43.7M
FY25 Q4 $39.2M
FY26 Q1 $51.5M
FY26 Q2 $105M
FY26 Q3 $102.2M
Revenue growth, TTM YoY Kymera Therapeutics, Inc.
-100% -50% 0% 50% 100% 150% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 67.8% Revenue growth, TTM YoY, FY24 Q1: 70.2% Revenue growth, TTM YoY, FY24 Q2: 71.4% Revenue growth, TTM YoY, FY24 Q3: 86.9% Revenue growth, TTM YoY, FY24 Q4: -40.1% Revenue growth, TTM YoY, FY25 Q1: -25.8% Revenue growth, TTM YoY, FY25 Q2: -49.5% Revenue growth, TTM YoY, FY25 Q3: -50.1% Revenue growth, TTM YoY, FY25 Q4: -16.7% Revenue growth, TTM YoY, FY26 Q1: -12.6% Revenue growth, TTM YoY, FY26 Q2: 134.8% Revenue growth, TTM YoY, FY26 Q3: 133.8% 133.8%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 67.8%
FY24 Q1 70.2%
FY24 Q2 71.4%
FY24 Q3 86.9%
FY24 Q4 -40.1%
FY25 Q1 -25.8%
FY25 Q2 -49.5%
FY25 Q3 -50.1%
FY25 Q4 -16.7%
FY26 Q1 -12.6%
FY26 Q2 134.8%
FY26 Q3 133.8%
Operating margin (TTM) Kymera Therapeutics, Inc.
-1000% -500% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -210.6% Operating margin (TTM), FY24 Q1: -224.2% Operating margin (TTM), FY24 Q2: -209.6% Operating margin (TTM), FY24 Q3: -228.6% Operating margin (TTM), FY24 Q4: -555.8% Operating margin (TTM), FY25 Q1: -472.5% Operating margin (TTM), FY25 Q2: -697.5% Operating margin (TTM), FY25 Q3: -759.7% Operating margin (TTM), FY25 Q4: -891.1% Operating margin (TTM), FY26 Q1: -697.7% Operating margin (TTM), FY26 Q2: -333.5% Operating margin (TTM), FY26 Q3: -396.0% -396.0%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -210.6%
FY24 Q1 -224.2%
FY24 Q2 -209.6%
FY24 Q3 -228.6%
FY24 Q4 -555.8%
FY25 Q1 -472.5%
FY25 Q2 -697.5%
FY25 Q3 -759.7%
FY25 Q4 -891.1%
FY26 Q1 -697.7%
FY26 Q2 -333.5%
FY26 Q3 -396.0%
FCF margin (TTM) Kymera Therapeutics, Inc.
-600% -400% -200% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -174.7% FCF margin (TTM), FY24 Q1: -171.7% FCF margin (TTM), FY24 Q2: -155.8% FCF margin (TTM), FY24 Q3: -169.2% FCF margin (TTM), FY24 Q4: -440.5% FCF margin (TTM), FY25 Q1: -407.5% FCF margin (TTM), FY25 Q2: -565.7% FCF margin (TTM), FY25 Q3: -526.4% FCF margin (TTM), FY25 Q4: -597.7% FCF margin (TTM), FY26 Q1: -474.0% FCF margin (TTM), FY26 Q2: -226.6% FCF margin (TTM), FY26 Q3: -282.6% -282.6%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -174.7%
FY24 Q1 -171.7%
FY24 Q2 -155.8%
FY24 Q3 -169.2%
FY24 Q4 -440.5%
FY25 Q1 -407.5%
FY25 Q2 -565.7%
FY25 Q3 -526.4%
FY25 Q4 -597.7%
FY26 Q1 -474.0%
FY26 Q2 -226.6%
FY26 Q3 -282.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 3 34 73 47 79 47 39 102
Gross profit — — — 0 0 0 0 0
EBITDA −41 −45 −98 −158 −162 −254 −341 −398
Operating income −42 −46 −101 −161 −166 −262 −349 −405
Net income −41 −46 −100 −155 −147 −224 −311 −349
Diluted EPS −$2.43 −$3.15 −$2.09 −$2.87 −$2.52 −$2.98 −$3.69 −$3.62
Growth (year on year)
Revenue — +>999% +114.0% −35.7% +67.8% −40.1% −16.7% +133.8%
Margins
Gross margin — — — 0.0% 0.0% 0.0% 0.0% 0.0%
EBITDA margin <−999% −130.9% −134.7% −338.0% −206.1% −540.2% −869.9% −388.9%
Operating margin <−999% −136.1% −138.0% −344.4% −210.6% −555.8% −891.1% −396.0%
Net margin <−999% −134.0% −137.6% −330.6% −187.0% −475.6% −794.0% −341.8%
Free-cash-flow margin 592.1% 232.2% −179.2% −333.0% −174.7% −440.5% −597.6% −282.6%
Cash flow
Cash from operations 18 88 −129 −153 −103 −195 −233 −288
Capital spending 1 9 2 3 34 13 1 1
Free cash flow 17 79 −131 −156 −137 −207 −234 −289
Stock-based pay 1 5 25 35 43 55 60 68
Free cash flow after stock pay 16 74 −156 −191 −180 −262 −294 −357
Balance sheet
Cash 76 31 48 68 110 120 357 373
Total debt 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −76 −31 −48 −68 −110 −120 −357 −373
Diluted shares 17m 17m 48m 54m 58m 75m 84m 96m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · September 30, 2026
What it owns · $1.8bn
Short-term assets $999mLonger-term assets $769m
What it owes, and who funded it · $1.8bn
Short-term liabilities $90mLonger-term liabilities $63mShareholders' equity $1.6bn
  • Short-term assets cover short-term liabilities $999m of assets due within a year against $90m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $999m short-term assets against $63m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Kymera Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+17.6%
year over year
R&D spending
420.6%
of revenue
Days sales outstanding
70 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated KYMR XNCR SEPN AGIO FDMT SPRY Median
Revenue, last 12 months $102m $105m $99m $98m $92m $117m $56m
Revenue growth, last 12 months 133.8% −28.6% >999% 140.6% >999% 4.1% 12.6%
Revenue growth, 3-year average 29.7% −2.5% — 69.6% 242.8% 711.3% 13.7%
Revenue growth, latest quarter −100.0% 17.5% >999% 259.3% >999% 114.2% 10.2%
Gross margin 0.0% — — 92.0% — — 82.9%
Operating margin −396.0% −205.8% −44.0% −466.8% −214.2% −185.0% −189.4%
Operating margin, 3-year average −461.5% −136.0% <−999% −963.3% <−999% <−999% −363.5%
Net margin −341.8% −155.6% −24.5% −418.2% −194.7% −184.2% −169.8%
Cash from operations / revenue −281.3% −196.1% 107.2% −366.7% −169.6% −168.0% −168.0%
Free-cash-flow margin −282.6% −198.4% 106.3% −371.4% −169.6% −168.1% −162.4%
Free-cash-flow margin, 3-year average −326.1% −128.0% — −784.8% <−999% <−999% −310.0%
Stock pay / revenue 66.7% 37.2% 16.5% 59.0% 22.2% 26.7% 20.0%
Change in share count 17.6% 5.2% — 0.4% 15.9% −3.9% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 133.8% 12.6% 33 of 172
Change in growth rate Growth -1.1pp -0.1pp 91 of 172
Gross margin Profitability 0.0% 82.4% 75 of 75
Operating margin Profitability -396.0% -189.4% 115 of 175
Net margin Profitability -341.8% -157.3% 115 of 180
Free-cash-flow margin Cash generation -282.6% -145.4% 111 of 176
Stock pay as % of revenue Cash generation 66.7% 19.2% 125 of 179
Change in share count Balance sheet 17.6% 7.9% 111 of 156
Days sales outstanding Balance sheet 70 days 75 days 49 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$11.1B
Institutions reporting
275
Shares held vs prior quarter
▲ 0.7%
Positions opened / closed
44 / 26

Top buyers and sellers, Q2 2026: 141 institutions bought and 109 sold ; the biggest buyer was Price T Rowe Associates Inc (+1.1M shares) and the biggest seller Atlas Venture Life Science Advisors, LLC (−1.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $1.4B 12.3M 12.8% ▲ 5.5%
Baker Bros. Advisors LP $993M 8.7M 9.0% 0.0%
Avoro Capital Advisors LLC $857M 7.5M 7.7% 0.0%
Price T Rowe Associates Inc $816M 7.1M 7.4% ▲ 17.4%
T. Rowe Price Investment Management, Inc. $718M 6.3M 6.5% ▲ 14.5%
Blackrock, Inc. $635M 5.5M 5.7% ▲ 9.4%
Bvf Inc $444M 3.9M 4.0% ▼ 29.6%
Wellington Management Group LLP $421M 3.7M 3.8% ▼ 5.5%
Vanguard Portfolio Management LLC $343M 3.0M 3.1% ▲ 4.1%
Siren, L.L.C. $337M 2.9M 3.0% ▼ 7.9%
Vanguard Capital Management LLC $336M 2.9M 3.0% ▲ 1.8%
Atlas Venture Life Science Advisors, LLC $327M 2.8M 2.9% ▼ 37.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kymera Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $172M 2 trades by 1 insider, last 12 months Insider sales History → $473M 274 trades by 11 insiders · 58% under pre-set plans
Net ▼ $301M net selling
Insider Date Trade Shares Price Value
Mainolfi Nello Chief Executive Officer October 1, 2026 Sell pre-set plan 262 $116.12 $30,423
Mainolfi Nello Chief Executive Officer October 1, 2026 Sell pre-set plan 8,230 $115.40 $949,742
Mainolfi Nello Chief Executive Officer October 1, 2026 Sell pre-set plan 7,601 $114.43 $869,782
Mainolfi Nello Chief Executive Officer October 1, 2026 Sell pre-set plan 4,876 $113.24 $552,158
Mainolfi Nello Chief Executive Officer October 1, 2026 Sell pre-set plan 5,506 $112.42 $618,985
Mainolfi Nello Chief Executive Officer October 1, 2026 Sell pre-set plan 3,525 $111.44 $392,826
Adams Brian Chief Legal Officer September 4, 2026 Sell 2,137 $117.57 $251,247
Adams Brian Chief Legal Officer September 4, 2026 Sell 3,025 $116.81 $353,350
Adams Brian Chief Legal Officer September 4, 2026 Sell 1,209 $115.55 $139,700
Mainolfi Nello Chief Executive Officer July 7, 2026 Sell pre-set plan 50,000 $119.00 $6M
Mainolfi Nello Chief Executive Officer July 1, 2026 Sell pre-set plan 3,336 $116.56 $388,844
Mainolfi Nello Chief Executive Officer July 1, 2026 Sell pre-set plan 24,105 $114.96 $2.8M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 15, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • August 5, 2026
  • April 30, 2026
  • February 26, 2026
  • January 13, 2026
  • November 4, 2025

Recent SEC filings

Data status

When each part of this page on Kymera Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Kymera Therapeutics, Inc. in brief

What does Kymera Therapeutics, Inc. do?
Kymera Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Kymera Therapeutics, Inc.'s stock ticker?
Kymera Therapeutics, Inc. trades under the ticker KYMR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Kymera Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Kymera Therapeutics, Inc. reported revenue of $102M, 133.8% higher than a year earlier, according to its SEC filings.
What is Kymera Therapeutics, Inc.'s free cash flow?
Kymera Therapeutics, Inc.'s free-cash-flow margin is -282.6% of revenue over the trailing twelve months, ranking 111 of the 176 biotechnology companies we cover.
Who are Kymera Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Baker Bros. Advisors LP and Avoro Capital Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Kymera Therapeutics, Inc.'s market cap?
On November 2, 2026, Kymera Therapeutics, Inc.'s market capitalisation was about $12.3B and net debt of -$373M. Market figures come from third-party market data and may be delayed.
Who are Kymera Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Kymera Therapeutics, Inc. are Xencor Inc, Septerna, Inc., Agios Pharmaceuticals, Inc., 4d Molecular Therapeutics, Inc. and ARS Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against Kymera Therapeutics, Inc.'s.
Are insiders buying or selling Kymera Therapeutics, Inc. stock?
Over the last 12 months, Kymera Therapeutics, Inc.'s directors and officers reported 2 open-market purchases and 274 sales on Form 4. The insider trading page charts every trade.
When is Kymera Therapeutics, Inc.'s next earnings date?
Around January 15, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kymera Therapeutics, Inc. announces its own schedule.